Neoadjuvant vs adjuvant chemotherapy for muscle-invasive bladder cancer: a propensity matched analysis.
CONCLUSIONS: The use of NAC+RC was associated with improved OS compared to RC+AC for patients diagnosed with T2-T4, N0, M0 bladder cancer. The increased survival benefit associated with NAC compared to AC among patients undergoing RC may be due to decreased progression to node positivity and pathological downstaging.
PMID: 32026665 [PubMed - as supplied by publisher]
Source: Minerva Urologica e Nefrologica - Category: Urology & Nephrology Tags: Minerva Urol Nefrol Source Type: research
More News: Academia | Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Insurance | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Urology & Nephrology